Annovis Bio (NYSE: ANVS), a late-stage biotechnology company specializing in the development of innovative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), will be presenting the results of its latest Alzheimer’s study at the 2024 Alzheimer’s Association International Conference® (AAIC). The conference is scheduled to take place from July 28 to August 1, 2024, in Philadelphia and will also offer online participation. AAIC is a premier global event for the presentation of cutting-edge research in the field of dementia, bringing together scientists, clinicians, and industry leaders to share their findings and explore new treatment strategies.
Annovis Bio’s presentation will be delivered by Dr. Cheng Fang, the company’s Senior Vice President of Research & Development. The extended 45-minute session is slated to begin at 8 a.m. on July 31. Dr. Fang will be joined by two distinguished colleagues: Kathleen A. Welsh-Bohmer, PhD, a professor of psychiatry and neurology at Duke University, and Maria L. Maccecchini, PhD, the founder and president of Annovis Bio. Their presentation, titled “Data from Phase 2/3 Clinical Study in Mild to Moderate Alzheimer’s Disease,” will provide a comprehensive overview of the significant findings from Annovis Bio’s recent studies on the drug Buntanetap, focusing on its efficacy and safety in patients with mild Alzheimer’s disease, including both APOE4 carriers and noncarriers.
The presentation is expected to highlight key data from the phase 2/3 clinical study, emphasizing the potential of Buntanetap as a novel treatment for Alzheimer’s disease. The study’s results indicate that Buntanetap may offer a promising approach to managing symptoms and slowing the progression of AD, which has long been a challenging area for medical research and drug development. The team will delve into the details of the drug’s mechanism of action, which aims to protect nerve cells and improve cognitive function, and discuss its safety profile, which has shown encouraging results in clinical trials.
AAIC 2024 will gather a diverse group of experts in dementia research, providing a unique platform for Annovis Bio to present its findings to a wide audience. The conference is known for its role in fostering collaboration and innovation in the field of dementia research, and this year’s event promises to continue that tradition. Attendees will have the opportunity to engage with the latest research, discuss new ideas, and explore the future directions of Alzheimer’s disease treatment.
“We are eagerly anticipating the opportunity to present our phase 2/3 study results at such a renowned conference,” said Dr. Cheng Fang in the press release. “The 45-minute session format is particularly valuable as it allows us to share our data in a detailed and meaningful way. We are looking forward to engaging with the scientific community and discussing the implications of our findings for the future of Alzheimer’s treatment.”
Dr. Welsh-Bohmer’s and Dr. Maccecchini’s participation in the presentation underscores the collaborative effort that has gone into the development of Buntanetap and highlights the importance of multi-disciplinary approaches in tackling complex diseases like Alzheimer’s. Their insights will add depth to the discussion and provide valuable perspectives on the implications of the study’s findings for the broader field of neurodegenerative disease research.
In addition to presenting at AAIC, Annovis Bio is committed to continuing its research and development efforts aimed at discovering and developing therapies that can significantly improve the lives of patients suffering from neurodegenerative diseases. The company’s pipeline includes a range of potential treatments that are being evaluated for their ability to target the underlying mechanisms of diseases like Alzheimer’s and Parkinson’s, offering hope for new and more effective therapies in the future.
As the conference date approaches, Annovis Bio is preparing to share its latest advances with the global scientific community, contributing to the collective effort to find better treatments for Alzheimer’s disease and other neurodegenerative disorders. The upcoming presentation at AAIC 2024 represents a significant milestone for the company and an important step forward in its mission to develop therapies that can make a real difference in the lives of patients and their families.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by IBN – (biomedwire.com)
